Details

Autor(en) / Beteiligte

• Shein, Aye Mya Sithu
• Wannigama, Dhammika Leshan
• Hurst, Cameron
• Monk, Peter N.
• Amarasiri, Mohan
• Badavath, Vishnu Nayak
• Phattharapornjaroen, Phatthranit
• Ditcham, William Graham Fox
• Ounjai, Puey
• Saethang, Thammakorn
• Chantaravisoot, Naphat
• Thuptimdang, Wanwara
• Luk-in, Sirirat
• Nilgate, Sumanee
• Rirerm, Ubolrat
• Tanasatitchai, Chanikan
• Kueakulpattana, Naris
• Laowansiri, Matchima
• Liao, Tingting
• Kupwiwat, Rosalyn
• Rojanathanes, Rojrit
• Ngamwongsatit, Natharin
• Thammahong, Arsa
• Ishikawa, Hitoshi
• Pletzer, Daniel
• Leelahavanichkul, Asada
• Ragupathi, Naveen Kumar Devanga
• Wapeesittipan, Pattama
• Ali Hosseini Rad, S.M.
• Kanjanabuch, Talerngsak
• Storer, Robin James
• Miyanaga, Kazuhiko
• Cui, Longzhu
• Hamamoto, Hiroshi
• Higgins, Paul G.
• Kicic, Anthony
• Chatsuwan, Tanittha
• Hongsing, Parichart
• Abe, Shuichi

Titel

Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection

Ist Teil von

• Biomedicine & pharmacotherapy, 2023-12, Vol.168, p.115793, Article 115793

Ort / Verlag

Elsevier Masson SAS

Erscheinungsjahr

2023

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration. Recently, adjuvants like CaEDTA have shown the ability to enhance the effectiveness of combined antimicrobial agents. Here, we tested a phage-adjuvant combination and demonstrated the effectiveness of intranasally inhaled phage (KKP10) + CaEDTA in addition to ceftazidime/avibactam (CZA) for chronic P. aeruginosa lung infections. The results emphasize that intranasal inhalation of phage along with CaEDTA can successfully re-sensitize MDR P. aeruginosa to CZA in a triple combination treatment. This promising approach shows potential as a therapy for chronic respiratory tract infections. [Display omitted] •New treatments needed for multidrug-resistant Pseudomonas aeruginosa infections.•Phage therapy is limited due to the resistance and biofilm penetration.•CaEDTA demonstrated the ability to enhance the effectiveness of antibiotics.•Inhaling phage + CaEDTA restores P. aeruginosa sensitivity to Ceftazidime/Avibactam.•This shows potential as a therapy for chronic respiratory tract infections.